key: cord-1032587-dp2bu7xa
authors: Teng, Jialin; Dai, Jin
title: SARS-CoV-2 serological cross-reactivity with autoantibodies – Authors' reply
date: 2020-12-24
journal: Lancet Rheumatol
DOI: 10.1016/s2665-9913(20)30359-3
sha: 1d06bc23777210adf4d652feaa2cecd759dc6e74
doc_id: 1032587
cord_uid: dp2bu7xa

nan

www.thelancet.com/rheumatology Vol 3 January 2021

We thank Kay Weng Choy for the interest in our work and we agree that the results of the chemical assays should consider endogenous compounds. However, performance analysis of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological assay that we used in our experiment showed that icterus and lipaemia were minimally affected, but false positive results can occur as a result of severe haemolysis. Although the SARS-CoV-2 test is not specific, a specificity of 91% still has a high positive predictive value, and we did not identify any false positive findings in the investigated population, which is as expected due to the absence of COVID-19 infection in patients when the samples were taken. We acknowledge and share the concerns about the negative predictive value due to the assay sensitivity of 89% but we believe the test is still a viable option for large-scale screening in an asymptomatic population. Indeed, specificity and sensitivity must be accurately identified in a lowprevalence setting. 4 Nevertheless, the purpose of our analysis was not to show that this serological test for COVID-19 should be used alone to diagnose patients. We wanted to show that there is no cross-reactivity with autoantibodies from autoimmune disease, and we believe that with the further clarifications described here we can still conclude that this absence of cross-reactivity is likely to be the case.

Clinical validation and performance evaluation of the automated vitros total anti-SARS-CoV-2 antibodies assay for screening of serostatus in COVID-19

Antibodies are forever: a study using 12-26-year-old expired antibodies

Common variable immunodeficiency in systemic lupus erythematosus

SARS-CoV-2 serology: much hype, little data

We declare no competing interests.